A landmark ruling by Japan’s IP High Court awarded record-breaking $150 million damages in the Nalfurafine (Remitch®) patent dispute. This case reshapes how pharmaceutical companies approach patent term extensions, generic entry strategies, and IP litigation risks.
Tirzepatide is not Lilly’s only contender in this field; its small-molecule agonist orforglipron also met primary endpoints in studies and is poised for regulatory submission and potential approval.
F.Hoffmann-La Roche(Roche) disclosed two patent applications, WO2025093625A1 and WO2025104149A1, covering a series of novel macrocyclic KRAS G12C inhibitors.
Eisbach Bio GmbH has disclosed two patent applications primarily focused on the use of ALC1 inhibitors in cancer treatment: WO2025088087A1 and WO2025088175A1.
Suzetrigine is the first non-opioid novel pain medication approved in over two decades for pain management; however, its efficacy appears to be limited.
Patsnap Eureka LS marks our transformation from a large language model into an intelligent AI Agent platform, purpose-built for the biopharmaceutical industry.
On June 4, 2025, the CAFC issued a precedential decision in a patent infringement case involving mRNA-based COVID-19 vaccines, addressing whether the patentee’s “custom” definition of a term constituted infringement.